7BDV image
Deposition Date 2020-12-22
Release Date 2021-03-03
Last Version Date 2024-11-13
Entry Detail
PDB ID:
7BDV
Title:
Structure of Can2 from Sulfobacillus thermosulfidooxidans in complex with cyclic tetra-adenylate (cA4)
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.02 Å
R-Value Free:
0.29
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Can2
Chain IDs:A, B, C, D
Chain Length:366
Number of Molecules:4
Biological Source:Sulfobacillus thermosulfidooxidans
Polymer Type:polyribonucleotide
Molecule:Cyclic tetraadenosine monophosphate (cA4)
Chain IDs:E (auth: F), F (auth: H)
Chain Length:4
Number of Molecules:2
Biological Source:synthetic construct
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
MSE A MET modified residue
Peptide-like Molecules
PRD_002431
Primary Citation
The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
Nucleic Acids Res. 49 2777 2789 (2021)
PMID: 33590098 DOI: 10.1093/nar/gkab073

Abstact

Cells and organisms have a wide range of mechanisms to defend against infection by viruses and other mobile genetic elements (MGE). Type III CRISPR systems detect foreign RNA and typically generate cyclic oligoadenylate (cOA) second messengers that bind to ancillary proteins with CARF (CRISPR associated Rossman fold) domains. This results in the activation of fused effector domains for antiviral defence. The best characterised CARF family effectors are the Csm6/Csx1 ribonucleases and DNA nickase Can1. Here we investigate a widely distributed CARF family effector with a nuclease domain, which we name Can2 (CRISPR ancillary nuclease 2). Can2 is activated by cyclic tetra-adenylate (cA4) and displays both DNase and RNase activity, providing effective immunity against plasmid transformation and bacteriophage infection in Escherichia coli. The structure of Can2 in complex with cA4 suggests a mechanism for the cA4-mediated activation of the enzyme, whereby an active site cleft is exposed on binding the activator. These findings extend our understanding of type III CRISPR cOA signalling and effector function.

Legend

Protein

Chemical

Disease

Primary Citation of related structures